<p>Genprex Inc. announced that IP Australia has issued a Notice of Acceptance for its patent application covering the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies for the treatment of cancers. This development provides additional intellectual property protection for the therapeutic combination currently being evaluated in the Acclaim-3 clinical trial. Similar claims have already been granted in the U.S. and Korea, and further patent applications are being pursued in other key international markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA83841) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

ARKG

Reuters

Ark Genomic Revolution ETF

VG Health

iShares Biotechnology ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Genprex

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Genprex Announces IP Australia's Acceptance of Patent Application for Reqorsa® Gene Therapy and PD-L1 Antibody Combination in Cancer Treatment